Stock Research: Champions Oncology

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Champions Oncology

NasdaqCM:CSBR US15870P3073
89
  • Value
    86
  • Growth
    59
  • Safety
    Safety
    16
  • Combined
    61
  • Sentiment
    89
  • 360° View
    360° View
    89
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Champions Oncology, Inc. is a preclinical and clinical research services provider specializing in oncology drug development. The company offers advanced technology solutions and products for personalized oncology drug development. It operates in the biotechnology and pharmaceutical industries. In the last fiscal year, the company had a market cap of $108 million, profits of $21 million, and revenue of $50 million, with 210 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 89 (better than 89% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Champions Oncology are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Champions Oncology. The consolidated Growth Rank has a good rank of 59, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 59% of competitors in the same industry. The consolidated Safety Rank at 86 means that the company has a financing structure that is safer than 86% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 89, which means that professional investors are more optimistic about the stock than for 89% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 16, meaning that the share price of Champions Oncology is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 84% of alternative stocks in the same industry. ...read more

more
Index
Moonshot Tech
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
16 10 42 37
Growth
59 97 25 61
Safety
Safety
86 1 100 100
Sentiment
89 72 18 25
360° View
360° View
89 54 11 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
71 71 3 31
Opinions Change
50 50 95 9
Pro Holdings
n/a 58 1 43
Market Pulse
82 52 55 94
Sentiment
89 72 18 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
16 10 42 37
Growth
59 97 25 61
Safety Safety
86 1 100 100
Combined
61 14 23 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
20 23 1 24
Price vs. Earnings (P/E)
81 64 87 93
Price vs. Book (P/B)
6 1 1 1
Dividend Yield
1 1 1 1
Value
16 10 42 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
84 63 48 43
Profit Growth
9 98 21 98
Capital Growth
15 34 25 29
Stock Returns
89 91 61 43
Growth
59 97 25 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
71 46 100 100
Refinancing
9 6 1 7
Liquidity
98 8 80 80
Safety Safety
86 1 100 100

Similar Stocks

Discover high‑ranked alternatives to Champions Oncology and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.